Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Nanobodies’ herald a new era in cancer therapy

12.05.2004


Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects. Researchers at VIB (the Flanders Interuniversity Institute for Biotechnology) are now developing ‘nanobodies’ − a new generation of drugs consisting of extremely small antibodies that target tumour cells very specifically.



The vast majority of the current medicines for treating tumours − the so-called chemotherapeutics − are seldom specific. Indeed, because a chemotherapy treatment is not only toxic to cancer cells but to the body’s normal cells as well, patients often experience severe side effects. The VIB research team under the direction of Hilde Revets and Patrick De Baetselier (Department of Molecular and Cellular Interactions, Free University of Brussels) is searching − successfully − for new, specific, effective cancer therapies.

For several years now, the leading strategy in the treatment of cancer has been based on the production of antibodies, which are protective substances produced in the organism to defend against intruding foreign bodies − protecting us against infections arising from bacteria and viruses. Antibodies can also react with tumour-specific substances that appear only on the cancer cell membrane. These ingenious antibodies seek out and bind very specifically to the cancer cells. As a result, the tumour is removed in a highly targeted, specific manner. At the moment, ten such medicines are available to patients. But even though these antibody medicines are a good step in the right direction, there is clearly room for improvement. The antibodies that are being used are large proteins that have difficulty penetrating tumours. In addition, their complex structure makes large-scale production very difficult and expensive.


In order to cope with these problems, the VIB researchers are using camel antibodies. Extremely small compared to conventional antibodies, this unique class of antibodies has been renamed ‘nanobodies’. Having all the advantages of the conventional antibodies, nanobodies also have several more important characteristics: they are small and they keep their tumour-specific character. At the same time, they are very stable, soluble proteins that are much easier and less expensive to produce than conventional antibodies. So, researchers have recently begun to evaluate nanobodies as anti-cancer medicines. The first results look promising: in experiments conducted on mice, a tumour with a certain protein on its membrane was successfully counteracted through administration of a nanobody directed against this protein.

To translate these results into a possible application for humans, VIB is collaborating with Ablynx, a company established by VIB and GIMV in 2001 with the aim of marketing the nanobody technology. Today, Ablynx has already developed nanobodies against 16 different therapeutic targets that represent a wide range of diseases in humans. Two of these nanobodies are in the pre-clinical phase and, according to plan, will be ready to be clinically tested next year.

These recent results are a new step toward the development of medicines based on nanobodies. In addition to cancer, other life-threatening diseases − such as certain inflammatory diseases, or heart and vascular diseases − are possibly eligible for a medical treatment with nanobodies.

Ann Van Gysel | alfa
Further information:
http://www.vib.be/

More articles from Health and Medicine:

nachricht Infants later diagnosed with autism follow adults’ gaze, but seldom initiate joint attention
24.05.2019 | Schwedischer Forschungsrat - The Swedish Research Council

nachricht When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New studies increase confidence in NASA's measure of Earth's temperature

A new assessment of NASA's record of global temperatures revealed that the agency's estimate of Earth's long-term temperature rise in recent decades is accurate to within less than a tenth of a degree Fahrenheit, providing confidence that past and future research is correctly capturing rising surface temperatures.

The most complete assessment ever of statistical uncertainty within the GISS Surface Temperature Analysis (GISTEMP) data product shows that the annual values...

Im Focus: The geometry of an electron determined for the first time

Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.

The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

On Mars, sands shift to a different drum

24.05.2019 | Physics and Astronomy

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema

24.05.2019 | Medical Engineering

Chemical juggling with three particles

24.05.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>